A carregar...
Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
Brentuximab vedotin (BV) is the first approved novel agent for salvage treatment of relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT). In this study, a literature‐based analysis was undertaken to assess, via an indirect treatment comparis...
Na minha lista:
| Publicado no: | Br J Haematol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7028067/ https://ncbi.nlm.nih.gov/pubmed/31588564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16201 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|